ClinicalTrials.gg
CompletedNCT00715403Updated Dec 2, 2014Results posted

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

A Phase 1 interventional study of BIBF 1120 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-02.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters.

Secondary objectives are the collection of further safety data (vital signs), efficacy data and the determination of pharmacokinetic characteristics during long-term therapy with BIBF 1120.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 41 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with advanced solid tumours who have completed a previous study with BIBF 1120. The patients should not have progression of their underlying tumour disease unless there is evidence for significant clinical benefit (e.g. symptom improvement) from treatment with BIBF 1120.
  2. Age 18 years or older
  3. (ECOG, R01-0787) performance score \<= 2
  4. Patients must have given written (which must be consistent with ICH-GCP and local legislation)

Exclusion criteria

Exclusion Criteria:

  1. Time elapsed from last administration of BIBF 1120 in the previous trial to start of treatment in the present trial exceeds four weeks
  2. Presence of drug related toxicity > grade 2 CTC from previous therapy with BIBF 1120 or presence of drug related continuous toxicity of grade 2 for seven or more consecutive days which would preclude ongoing chronic therapy with BIBF 1120
  3. Active ulcers (gastro-intestinal tract, skin)
  4. Major injuries and surgery within the past three weeks with incomplete wound healing
  5. to BIBF 1120 or the of the trial drug
  6. Known secondary requiring therapy
  7. Active infectious disease
  8. Significant cardiovascular diseases (i.e. uncontrolled severe hypertension, unstable angina pectoris, history of myocardial infarction, congestive heart failure > II)
  9. Gastrointestinal disorders anticipated to interfere with the resorption of the study drug
  10. requiring therapy
  11. less than 1,500/mm3
  12. count less than 100,000/mm3
  13. greater than 1.5 mg/dl (> 26 µmol/L)
  14. Aspartate amino transferase () and/or alanine amino transferase (ALT) greater than 2.5 times the (if related to liver greater than five times the upper limit of normal)
  15. Serum creatinine greater than 2 mg/dl (> 176 µmol/L)
  16. Concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
  17. Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with the trial drug
  18. Patients who are sexually active and unwilling to use a medically acceptable method of
  19. Pregnancy or lactation
  20. Treatment with other drugs or participation in another clinical trial within the past four weeks before start of therapy (visit 2) or concomitantly with this trial (except for a previous study with BIBF 1120)
  21. Patients unable to comply with the protocol
  22. Active alcohol or drug abuse
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Enrollment
41 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1

    All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From signing the informed consent until final follow-up, up to 991 days

  2. Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2

    All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From signing the informed consent until final follow-up, up to 991 days

  3. Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3

    All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From signing the informed consent until final follow-up, up to 991 days

  4. Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4

    All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From signing the informed consent until final follow-up, up to 991 days

  5. Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5

    All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From signing the informed consent until final follow-up, up to 991 days

  6. Difference From Baseline for Liver Enzymes

    Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

    Time frame: From signing the informed consent until end of treatment, up to 991 days

  7. Difference From Baseline for Bilirubin, Creatinine and Glucose

    Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

    Time frame: From signing the informed consent until end of treatment, up to 991 days

  8. Difference From Baseline for Haemoglobin

    Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

    Time frame: From baseline until end of treatment, up to 991 days

  9. Difference From Baseline for Haematology and Differentials Parameters

    Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

    Time frame: From signing the informed consent until end of treatment, up to 991 days

  10. Difference From Baseline for Coagulation Parameters

    Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

    Time frame: From signing the informed consent until end of treatment, up to 991 days

  11. Difference From Baseline for Electrolytes

    Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

    Time frame: From signing the informed consent until end of treatment, up to 991 days

Secondary outcomes

  1. Clinically Relevant Abnormalities for Vital Signs

    Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

    Time frame: From baseline until final follow-up, up to 991 days

  2. Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)

    Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29

    Time frame: Just before drug administration every 28±7 days after day 29

  3. Unconfirmed Best Overall Response

    Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0). PD = Progressive disease.

    Time frame: Baseline until end of treatment, up to 991 days

  4. Unconfirmed Best Objective Response

    Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)

    Time frame: Baseline until end of treatment, up to 991 days

  5. Clinical Benefit

    Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).

    Time frame: Baseline until end of treatment, up to 991 days

  6. Confirmed Objective Response

    Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)

    Time frame: Baseline until end of treatment, up to 991 days

  7. Progression Free Survival

    Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease. PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier. Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.

    Time frame: First drug administration (in previous trial) until end of treatment, up to 1230 days

07

Results

Posted Dec 2, 2014

Participant flow

This was a multinational, open-label, uncontrolled, extension trial with Nintedanib in patients who had experienced a clinical benefit with Nintedanib (objective tumour response or disease stabilisation and/or symptom improvement) in either one out of five phase I or phase I/IIA clinical trials for advanced solid tumours at study entry.

Participant flow — Overall Study
Milestone50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Started11496191
Completed0000000
Not completed11496191
Withdrew: Progressive disease01395141
Withdrew: Dose limiting toxicity (dlt)0000010
Withdrew: Other adverse event than dlt1000020
Withdrew: Protocol violation0000010
Withdrew: Other reason not defined above0010110

Outcome measures

PrimaryIncidence and Intensity of Adverse Events With Highest CTCAE Grade 1

All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

Time frame:
From signing the informed consent until final follow-up, up to 991 days
Reported as:
Number · percentage of participants
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Dyspepsia1000011000
Fatigue10000331700
Nasopharyngitis1000003350
Anorexia10000110160
Hyperhidrosis1000011050
Diarrhoea01000445037100
Bronchitis010000000
Eye disorder00250000
Eyelid oedema00250000
Haemorrhoids00250050
Toothache00250000
Pyrexia0025111750
Muscle spasms0025110110
Neck pain00250000
Pain in extremity0025111750
Vulvovaginal dryness00250000
Arrhythmia00011000
Nausea0003367210
Vomiting000223350
Abdominal pain0001133110
Gastrooesophageal reflux disease00011000
Tooth discolouration00011000
Asthenia000113350
Xerosis00011000
Gastrointestinal infection00011000
Bone pain000221700
Arthralgia000115050
Musculoskeletal chest pain00011000
Myalgia0001100100
Dizziness00022050
Headache00011050
Anxiety00011000
Rales00011000
Nail disorder00011000
Rash00011000
Hot flush00011000
Vertigo00001700
Constipation000017160
Flatulence000017110
Gastric disorder00001700
Hypersensitivity00001700
Viral infection00001700
Musculoskeletal pain00001750
Balance disorder00001700
Carpal tunnel syndrome00001700
Sciatica00001700
Dysuria00001700
Dyspnoea00003300
Rash maculo-papular00001700
Sinus tachycardia0000050
Eye pain0000050
Visual impairment0000050
Abdominal distension0000050
Gastrointestinal haemorrhage0000050
Adverse drug reaction0000050
Chest pain0000050
Chills0000050
Hepatic pain0000050
Urinary tract infection0000050
Weight decreased00000110
Hyperglycaemia0000050
Muscular weakness00000110
Back pain0000050
Joint swelling0000050
Dysgeusia0000050
Peripheral sensory neuropathy0000050
Insomnia00000110
Haematuria0000050
Incontinence0000050
Cough0000050
Alopecia0000050
Dry skin0000050
Pruritus0000050
Conjunctivitis000000100
Haemoptysis000000100
SecondaryClinically Relevant Abnormalities for Vital Signs

Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

Time frame:
From baseline until final follow-up, up to 991 days
Reported as:
Number · percentage of participants
Clinically Relevant Abnormalities for Vital Signs
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Clinically Relevant Abnormalities for Vital Signs0.00.00.00.00.00.00.0
SecondaryPre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)

Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29

Time frame:
Just before drug administration every 28±7 days after day 29
Reported as:
Geometric mean · ng/mL
Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)
ng/mL50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)———7.54 ± 48.311.8 ± 33.511.0 ± 48.5—
SecondaryUnconfirmed Best Overall Response

Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0). PD = Progressive disease.

Time frame:
Baseline until end of treatment, up to 991 days
Reported as:
Number · percentage of participants
Unconfirmed Best Overall Response
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Complete response010000000
Partial response0000050
Stable disease100075330160
Non-evaluable, clinically non-progressive disease0025118350
PD or non-evaluable , clinically PD000111732100
Unknown000440420
SecondaryUnconfirmed Best Objective Response

Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)

Time frame:
Baseline until end of treatment, up to 991 days
Reported as:
Number · percentage of participants
Unconfirmed Best Objective Response
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
No10001005610053100
Yes010000050
Unknown000440420
SecondaryClinical Benefit

Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).

Time frame:
Baseline until end of treatment, up to 991 days
Reported as:
Number · percentage of participants
Clinical Benefit
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
No00000110
Yes10010010010010089100
SecondaryConfirmed Objective Response

Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)

Time frame:
Baseline until end of treatment, up to 991 days
Reported as:
Number · percentage of participants
Confirmed Objective Response
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
No10001005610058100
Yes010000000
Unknown000440420
SecondaryProgression Free Survival

Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease. PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier. Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.

Time frame:
First drug administration (in previous trial) until end of treatment, up to 1230 days
Reported as:
Number · percentage of participants
Progression Free Survival
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Progression (RECIST)010025113342100
Death00000320
No progressive disease (RECIST) or death1000754467160
Unknown000450100
PrimaryIncidence and Intensity of Adverse Events With Highest CTCAE Grade 2

All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

Time frame:
From signing the informed consent until final follow-up, up to 991 days
Reported as:
Number · percentage of participants
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Fatigue000220110
Anorexia00000110
Diarrhoea0001133210
Bronchitis00001700
Nausea00000110
Vomiting0000050
Abdominal pain00011000
Asthenia0025110110
Gastrointestinal infection00001700
Bone pain00000110
Arthralgia0000050
Musculoskeletal chest pain00011000
Headache002511000
Constipation0000050
Flatulence00011000
Musculoskeletal pain0000050
Sciatica00000110
Dyspnoea000110110
Chest pain00011000
Urinary tract infection00250050
Weight decreased0000050
Back pain00011000
Peripheral sensory neuropathy00001700
Cough00000110
Haemoptysis0000050
Osteoarthritis00250000
Parotitis00011000
Osteolysis00011000
Abdominal pain upper00001700
Gastrointestinal disorder00001700
Groin pain00001700
Anaemia0000050
Neutropenia0000050
Oedema peripheral0000050
Gamma-glutamyltransferase increased0000050
Dehydration0000050
Productive cough0000050
Deep vein thrombosis0000050
Phlebitis superficial0000050
PrimaryIncidence and Intensity of Adverse Events With Highest CTCAE Grade 3

All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

Time frame:
From signing the informed consent until final follow-up, up to 991 days
Reported as:
Number · percentage of participants
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Gamma-glutamyltransferase increased100000000
Diarrhoea002511050
Diarrhoea infectious00250000
Dyspnoea00011050
Lymphopenia0000050
Constipation0000050
Haemorrhoids0000050
Ileus0000050
Subileus0000050
Vomiting0000050
Pneumonia0000050
Convulsion0000050
Renal failure00000110
Urinary tract obstruction0000050
Pleural effusion0000050
PrimaryIncidence and Intensity of Adverse Events With Highest CTCAE Grade 4

All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

Time frame:
From signing the informed consent until final follow-up, up to 991 days
Reported as:
Number · percentage of participants
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 40000000
PrimaryIncidence and Intensity of Adverse Events With Highest CTCAE Grade 5

All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).

Time frame:
From signing the informed consent until final follow-up, up to 991 days
Reported as:
Number · percentage of participants
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5
percentage of participants50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Subdural Haematoma0000050
Malignant neoplasm progression00000260
PrimaryDifference From Baseline for Liver Enzymes

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Time frame:
From signing the informed consent until end of treatment, up to 991 days
Reported as:
Median · U/L
Difference From Baseline for Liver Enzymes
U/L50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Alkaline phosphatase127.0 ± 0.011.9 ± 0.0-39.0 ± 70.5-21.2 ± 96.4-11.7 ± 81.016.0 ± 180.97.2 ± 0.0
Aspartate aminotransferase14.3 ± 0.013.7 ± 0.09.6 ± 18.06.8 ± 9.14.3 ± 41.015.9 ± 35.17.6 ± 0.0
Alanine aminotransferase10.6 ± 0.06.6 ± 0.00.6 ± 11.1-1.6 ± 18.89.1 ± 45.417.0 ± 33.612.4 ± 0.0
PrimaryDifference From Baseline for Bilirubin, Creatinine and Glucose

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Time frame:
From signing the informed consent until end of treatment, up to 991 days
Reported as:
Median · mg/dL
Difference From Baseline for Bilirubin, Creatinine and Glucose
mg/dL50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Bilirubin (total)0.5 ± 0.00.0 ± 0.00.0 ± 0.20.0 ± 0.30.1 ± 0.10.1 ± 0.30.0 ± 0.0
Creatinine-0.1 ± 0.0-0.3 ± 0.00.0 ± 0.2-0.1 ± 0.0-0.1 ± 0.2-0.1 ± 0.30.0 ± 0.0
Glucose (N=1,1,3,9,4,14,1)-60.0 ± 0.0-2.2 ± 0.028.9 ± 126.1-11.3 ± 75.1-76.5 ± 75.9-23.3 ± 52.2-40.0 ± 0.0
PrimaryDifference From Baseline for Haemoglobin

Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Time frame:
From baseline until end of treatment, up to 991 days
Reported as:
Median · g/dL
Difference From Baseline for Haemoglobin
g/dL50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Difference From Baseline for Haemoglobin-1.8 ± 0.01.4 ± 0.00.4 ± 2.31.0 ± 1.31.2 ± 0.7-0.2 ± 2.11.1 ± 0.0
PrimaryDifference From Baseline for Haematology and Differentials Parameters

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Time frame:
From signing the informed consent until end of treatment, up to 991 days
Reported as:
Median · 10^9 /L
Difference From Baseline for Haematology and Differentials Parameters
10^9 /L50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Platelets42.2 ± 0.011.1 ± 0.01.0 ± 83.7-2.5 ± 25.2-38.1 ± 39.911.2 ± 65.9-27.1 ± 0.0
White blood cell count-1.1 ± 0.0-0.7 ± 0.00.2 ± 2.9-0.8 ± 2.6-0.1 ± 5.60.7 ± 2.90.0 ± 0.0
Lymphocytes (N=1,1,4,9,4,17,1)-0.6 ± 0.0-0.4 ± 0.0-0.1 ± 2.01.0 ± 1.10.0 ± 1.60.6 ± 0.61.1 ± 0.0
Neutrophils (N=1,1,4,9,6,17,1)-4.1 ± 0.0-4.7 ± 0.00.9 ± 3.7-1.0 ± 5.6-2.4 ± 10.0-0.5 ± 3.0-1.2 ± 0.0
PrimaryDifference From Baseline for Coagulation Parameters

Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Time frame:
From signing the informed consent until end of treatment, up to 991 days
Reported as:
Median · sec
Difference From Baseline for Coagulation Parameters
sec50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
PT-INR (N=1,1,3,7,5,14,1)0.1 ± 0.00.1 ± 0.00.3 ± 0.60.1 ± 0.10.2 ± 0.5-0.0 ± 0.10.1 ± 0.0
Partial thromboplastin time (N=1,1,3,9,4,14,1)0.7 ± 0.02.6 ± 0.0-3.6 ± 6.71.9 ± 4.31.9 ± 4.31.5 ± 4.7-2.9 ± 0.0
PrimaryDifference From Baseline for Electrolytes

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Time frame:
From signing the informed consent until end of treatment, up to 991 days
Reported as:
Median · mmol/L
Difference From Baseline for Electrolytes
mmol/L50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Potassium (N=1,1,4,9,6,18,1)0.2 ± 0.0-0.3 ± 0.0-0.3 ± 2.10.1 ± 0.4-0.0 ± 1.10.1 ± 0.90.0 ± 0.0
Sodium (N=1,1,4,9,6,18,1)2.0 ± 0.01.0 ± 0.03.3 ± 5.20.0 ± 1.51.5 ± 6.0-1.3 ± 5.55.0 ± 0.0

Adverse events

Collected over From the first intake of trial medication until 28 days after last intake of medication, up to 1119 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50mg QD—0/1 (0%)1/1 (100%)
200mg QD—0/1 (0%)1/1 (100%)
100mg BID—0/4 (0%)4/4 (100%)
150mg BID—1/9 (11.1%)9/9 (100%)
200mg BID—0/6 (0%)6/6 (100%)
250mg BID—9/19 (47.4%)17/19 (89.5%)
300mg BID—0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
Event50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/10/10/40/90/65/190/1
OsteolysisMusculoskeletal and connective tissue disorders0/10/10/41/90/60/190/1
ConstipationGastrointestinal disorders0/10/10/40/90/62/190/1
Renal failureRenal and urinary disorders0/10/10/40/90/62/190/1
DyspnoeaRespiratory, thoracic and mediastinal disorders0/10/10/40/90/62/190/1
IleusGastrointestinal disorders0/10/10/40/90/61/190/1
SubileusGastrointestinal disorders0/10/10/40/90/61/190/1
VomitingGastrointestinal disorders0/10/10/40/90/61/190/1
PneumoniaInfections and infestations0/10/10/40/90/61/190/1
Urinary tract infectionInfections and infestations0/10/10/40/90/61/190/1
Most frequent other events
Showing 10 of 91
Most frequent other events
Event50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BID
ConjunctivitisEye disorders0/10/10/40/90/60/191/1
DiarrhoeaGastrointestinal disorders0/11/11/46/95/612/191/1
DyspepsiaGastrointestinal disorders1/10/10/41/90/60/190/1
FatigueGeneral disorders1/10/10/45/91/62/190/1
BronchitisInfections and infestations0/11/10/40/91/60/190/1
NasopharyngitisInfections and infestations1/10/10/40/92/61/190/1
Gamma-glutamyltransferase increasedInvestigations1/10/10/40/90/61/190/1
AnorexiaMetabolism and nutrition disorders1/10/10/41/90/65/190/1
MyalgiaMusculoskeletal and connective tissue disorders0/10/10/41/90/60/191/1
HaemoptysisRespiratory, thoracic and mediastinal disorders0/10/10/40/90/61/191/1

Baseline characteristics

Treated set which comprised of all patients who received at least one dose of Nintedanib in both their previous Nintedanib trial and in this extension trial

Age, Continuous
Age, Continuous(years)50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BIDTotal
Median75.0 (75 to 75)47.0 (47 to 47)65.5 (52 to 75)66.0 (52 to 78)63.5 (45 to 74)66.0 (41 to 80)67.0 (67 to 67)66.0 (41 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)50mg QD200mg QD100mg BID150mg BID200mg BID250mg BID300mg BIDTotal
Female01222108
Male1027418133
08

Study locations

11 sites
  • 1199.16.3306A Boehringer Ingelheim Investigational Site
    Bordeaux cedex, France
  • 1199.16.3311A Boehringer Ingelheim Investigational Site
    Clichy Cedex, France
  • 1199.16.3311B Boehringer Ingelheim Investigational Site
    Clichy Cedex, France
  • 1199.16.3313A Boehringer Ingelheim Investigational Site
    Paris Cedex 10, France
  • 1199.16.3313E Boehringer Ingelheim Investigational Site
    Paris Cedex 10, France
  • 1199.16.3302A Boehringer Ingelheim Investigational Site
    Paris cedex 15, France
  • 1199.16.3312A Boehringer Ingelheim Investigational Site
    Paris, France
  • 1199.16.49001 Boehringer Ingelheim Investigational Site
    Freiburg/Breisgau, Germany
  • 1199.16.49004 Boehringer Ingelheim Investigational Site
    Grosshansdorf, Germany
  • 1199.16.49008 Boehringer Ingelheim Investigational Site
    Tübingen, Germany
  • 1199.16.49005 Boehringer Ingelheim Investigational Site
    Wiesbaden, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a primary completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2008
First posted
Jul 15, 2008
Start
Oct 2004
Primary completionActual
Sep 2009
Results first posted
Dec 2, 2014
Last update
Dec 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00715403
First posted
Jul 15, 2008
Start date
Oct 2004
Primary completion
Sep 2009
Results posted
Dec 2, 2014
Last update
Dec 2, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion